APRINOIA Therapeutics Inc. (APRI)
APRINOIA Therapeutics was planning to go public, but the IPO was withdrawn on Oct 28, 2024.
IPO Price Range
$10.00 - $12.00
Shares Offered
500,000
Deal Size
$5.50M
APRINOIA Therapeutics Revenue
APRINOIA Therapeutics had revenue of $9.13M in the twelve months ending June 30, 2023. In the year 2022, APRINOIA Therapeutics had annual revenue of $394.00K, down -28.36%.
Revenue (ttm)
$9.13M
Revenue Growth
-28.36%
P/S Ratio
32.35
Revenue / Employee
$126,847
Employees
72
Market Cap
295.47M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 394.00K | -156.00K | -28.36% |
| Dec 31, 2021 | 550.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAPRI News
- 10 months ago - Aprinoia Therapeutics Starts $50 Million IPO For Neurodegenerative Disease Treatments - Seeking Alpha
- 10 months ago - Clinical-Stage Biotech Aprinoia Therapeutics Files for IPO - MarketWatch
- 10 months ago - APRINOIA Therapeutics IPO Registration Document (F-1) - SEC